Active surveillance for localized prostate cancer : a new paradigm for clinical management / Laurence Klotz, editor.
This book explores active surveillance in prostate cancer, covering patient selection, risk assessment, 'cancer hysteria' in patients, identifying triggers for intervention, use of PSA kinetics and MRI information and the roles of surveillance and focal therapy.
Saved in:
| Online Access: |
Full Text (via Springer) |
|---|---|
| Other Authors: | |
| Format: | eBook |
| Language: | English |
| Published: |
Cham :
Springer,
©2018.
|
| Edition: | 2nd ed. |
| Series: | Current clinical urology.
|
| Subjects: |
Table of Contents:
- Preface to Active Surveillance, Second Edition; Contents; Contributors; 1: Cancer Overdiagnosis and Overtreatment; Background; Cancer Overdiagnosis; Requirements for Overdiagnosis; Prevalence of Microfocal Disease; Disease Detection; Evidence that Early Detection Has Led to Overdiagnosis; References; 2: Can We Screen and Still Reduce Overdiagnosis?; Autopsy Studies of Subclinical Prostate Cancer; Natural History of Untreated Low-ƯRisk Prostate Cancer; Estimation of the Extent of Overdiagnosis; Who to Screen?; Family History of Prostate Cancer; Racial Differences on Prostate Cancer.
- Genetic Mutations Associating with Higher Risk of Prostate Cancer Is the Presence of a Risk Factor a License to Screen?; When to Screen?; Starting Screening, Baseline PSA at Younger Age; Screening Interval; Ending Age of Screening; How to Screen?; PSA-Based Prostate Cancer Risk Calculators; Novel Biomarkers for Prostate Cancer Prediction; Urine PCA3; Urine TMPRSS2-ERG; Prostate Health Index (PHI); Four-Kallikrein Panel (4 K); STHLM3; Which Novel Biomarker for Prostate Cancer Diagnosis Should We Choose?; Prostate Imaging: Multiparametric MRI of the Prostate; Conclusions.
- Patient-Physician Communication How Communication Can Influence Decision-Making; Shared Decision-Making; Guidelines; The United States; The Netherlands; Discussion; References; 5: Gleason 6 Tumors Should Still Be Labeled as Cancer; Introduction; Original and Modified Gleason Grading; Improved Prognosis of Current Gleason Score 6; Alternative Non-cancerous Terminology for Gleason 6 Cancer; Clinical Arguments Against Changing Gleason 6 Terminology; Morphological Arguments Against Changing Gleason 6 Terminology; A New Patient-Centric Simplified Prostate Cancer Grading System.
- Molecular Genetics of Gleason 6 Prostate Cancer Somatic Genetic Alterations; Molecular Subtypes of Prostate Cancer Identified by "Omics"; Other Rearrangements and Copy Number Alterations; Overall Percent of Genome Altered; Somatic Epigenetic Changes; Clonal Relationships Suggest a Common Origin for Gleason Score 7 Tumor Components; RNA Expression Profiles; Other Tissue-Based Molecular Markers; Conclusions/Summary; References; 6: Risk-Based Selection for Active Surveillance; Introduction; Patient Selection for Active Surveillance: Qualitative Considerations.